Bogart Wealth LLC Lowers Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Bogart Wealth LLC decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 73,681 shares of the biopharmaceutical company’s stock after selling 1,070 shares during the period. Bogart Wealth LLC’s holdings in Gilead Sciences were worth $5,969,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Verdence Capital Advisors LLC boosted its holdings in shares of Gilead Sciences by 18.2% during the 3rd quarter. Verdence Capital Advisors LLC now owns 13,426 shares of the biopharmaceutical company’s stock valued at $1,006,000 after acquiring an additional 2,069 shares during the last quarter. Mackenzie Financial Corp grew its position in Gilead Sciences by 2.7% in the 3rd quarter. Mackenzie Financial Corp now owns 491,927 shares of the biopharmaceutical company’s stock worth $36,043,000 after purchasing an additional 13,090 shares during the period. Brighton Jones LLC raised its stake in Gilead Sciences by 2.3% during the 3rd quarter. Brighton Jones LLC now owns 13,349 shares of the biopharmaceutical company’s stock valued at $1,000,000 after buying an additional 301 shares during the last quarter. WESPAC Advisors LLC bought a new position in shares of Gilead Sciences during the 3rd quarter valued at $219,000. Finally, Baystate Wealth Management LLC boosted its stake in shares of Gilead Sciences by 36.6% in the 3rd quarter. Baystate Wealth Management LLC now owns 578 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 155 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Trading Down 0.1 %

Gilead Sciences stock traded down $0.04 during trading on Thursday, reaching $64.88. 722,590 shares of the company were exchanged, compared to its average volume of 7,351,445. The company has a debt-to-equity ratio of 1.08, a current ratio of 0.98 and a quick ratio of 0.72. The stock’s 50 day simple moving average is $70.25 and its two-hundred day simple moving average is $75.60. The company has a market capitalization of $80.78 billion, a P/E ratio of 180.44, a PEG ratio of 1.31 and a beta of 0.22. Gilead Sciences, Inc. has a 52-week low of $64.33 and a 52-week high of $87.86.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. During the same quarter in the previous year, the company posted $1.37 EPS. The company’s revenue was up 5.3% compared to the same quarter last year. On average, equities research analysts expect that Gilead Sciences, Inc. will post 3.74 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be issued a $0.77 dividend. The ex-dividend date is Friday, June 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.75%. Gilead Sciences’s dividend payout ratio is presently 855.56%.

Insider Buying and Selling

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total value of $146,360.00. Following the sale, the insider now directly owns 100,936 shares in the company, valued at $7,386,496.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.29% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on GILD shares. Morgan Stanley cut their target price on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research report on Friday, April 26th. Barclays cut their price target on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a report on Monday, April 29th. Cantor Fitzgerald decreased their price objective on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 7th. Royal Bank of Canada lowered their price objective on Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating on the stock in a research report on Friday, April 26th. Finally, Truist Financial cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and decreased their target price for the stock from $91.00 to $82.00 in a research note on Thursday, February 22nd. Eleven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $83.69.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.